This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Insider Trading Alert - DVN, NUVA And SWN Traded By Insiders

NuVasive (NUVA) - FREE Research Report

Valentine Keith, who is President & COO at NuVasive, sold 5,000 shares at $35.00 on June 24, 2014. Following this transaction, the President & COO owned 84,785 shares meaning that the stake was reduced by 5.57% with the 5,000-share transaction.

Hannon Jason, who is EVP, General Counsel & Sec. at NuVasive, sold 8,781 shares at $35.00 on June 24, 2014. Following this transaction, the EVP, General Counsel & Sec. owned 35,390 shares meaning that the stake was reduced by 19.88% with the 8,781-share transaction.

Powers Russell, who is EVP, International at NuVasive, sold 9,526 shares at $35.00 on June 24, 2014. Following this transaction, the EVP, International owned 43,281 shares meaning that the stake was reduced by 18.04% with the 9,526-share transaction.

The shares most recently traded at $34.59, down $0.41, or 1.19% since the insider transaction. Historical insider transactions for NuVasive go as follows:

  • 4-Week # shares sold: 13,096
  • 12-Week # shares sold: 15,596
  • 24-Week # shares sold: 57,471

The average volume for NuVasive has been 343,400 shares per day over the past 30 days. NuVasive has a market cap of $1.7 billion and is part of the health care sector and health services industry. Shares are up 7.84% year-to-date as of the close of trading on Tuesday.

NuVasive, Inc., a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for the spine. Its products focus on applications for spine fusion surgery. Currently, there are 8 analysts who rate NuVasive a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NUVA - FREE

TheStreet Quant Ratings rates NuVasive as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full NuVasive Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs